<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006050</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068072</org_study_id>
    <secondary_id>FRE-FNCLCC-98012-PAC-ACCORD-04</secondary_id>
    <secondary_id>EU-20017</secondary_id>
    <nct_id>NCT00006050</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver</brief_title>
  <official_title>Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving drugs in different ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of liver perfusion using oxaliplatin plus&#xD;
      leucovorin and fluorouracil given by infusion in treating patients who have colorectal cancer&#xD;
      that has spread to the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy and tolerance of oxaliplatin by hepatic perfusion&#xD;
      combined with intravenous leucovorin calcium and fluorouracil in patients with liver&#xD;
      metastases from colorectal cancer.&#xD;
&#xD;
      OUTLINE: Patients receive oxaliplatin by hepatic perfusion over 2 hours on day 1 plus&#xD;
      leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2.&#xD;
      Treatment repeats every 14 days in the absence of disease progression or unacceptable&#xD;
      toxicity. If a good response is achieved after 8 courses of chemotherapy, patients may&#xD;
      undergo surgical resection of metastases.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 1999</start_date>
  <completion_date type="Actual">April 4, 2003</completion_date>
  <primary_completion_date type="Actual">December 31, 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven colorectal cancer metastatic to the liver&#xD;
        Unresectable disease Less than 50% invasion of the liver Measurable disease No prior&#xD;
        irradiation Largest diameter at least 20 mm No detectable extrahepatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Under 75 Performance status: WHO 0-2 Life expectancy: Greater&#xD;
        than 2 months Hematopoietic: WBC at least 4,000/mm3 Neutrophil count at least 1,500/mm3&#xD;
        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 35 micromoles/L Renal:&#xD;
        Creatinine less than 130 micromoles/L Cardiovascular: No severe cardiac insufficiency&#xD;
        Pulmonary: No respiratory disease that would preclude study Other: No other serious illness&#xD;
        that would preclude study No psychological illness that would preclude study No peripheral&#xD;
        neuropathy No prior malignancy not considered cured Not pregnant Fertile patients must use&#xD;
        effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        intravenous oxaliplatin No more than 1 prior regimen of intravenous chemotherapy for&#xD;
        metastatic disease Primary chemotherapy of fluorouracil allowed if stable or progressive&#xD;
        disease No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy&#xD;
        Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Ducreux, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. doi: 10.1200/JCO.2005.05.120. Epub 2005 Jul 11.</citation>
    <PMID>16009952</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2004</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

